Earnings Releases·Nov 4, 2026, 4:08 PM ET

Mineralys Therapeutics — Third Quarter 2026 Earnings Summary

Cash and investments decreased to $624.7 million as of September 30, 2026, from $656.6 million at year-end 2025, while R&D expenses fell to $22.7 million from $31.5 million due to the conclusion of the pivotal program; conversely, G&A expenses rose to $37.4 million from $9.7 million driven by commercialization preparations.
Net loss widened to $57.3 million ($0.64 per share) from $36.9 million ($0.52 per share) in the prior year period, accompanied by the introduction of a $98.3 million senior secured term loan and a total liability increase to $126.3 million.
The company confirmed sufficient liquidity to fund operations and the commercial launch of lorundrostat into 2028, with the PDUFA target date set for December 22, 2026, and launch preparations advancing on track.
Clinical data from the Phase 3 Launch-HTN trial showed 46% of participants achieved systolic blood pressure targets of <130 mmHg, while the company expanded its medical affairs and sales teams to support the pending approval.